Precigen, Inc. (PGEN) stock

PGENNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30239% above fair value

$4.54−0.12 (-2.58%)

Close on Nov 13, 2026Market cap $1.63BP/E 113.5Yield –

Precigen ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Precigen's ebitda for the twelve months ending Sep 30, 2026 was $38.08M. For fiscal 2025 it was -$107.31M. The highest annual figure on record is -$50.82M in fiscal 2013.

Annual ebitda

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$107.31M	–
FY2024	Dec 31, 2024	-$130.50M	–
FY2023	Dec 31, 2023	-$93.09M	–
FY2018	Dec 31, 2018	-$472.50M	–
FY2017	Dec 31, 2017	-$106.75M	–
FY2016	Dec 31, 2016	-$100.59M	–
FY2015	Dec 31, 2015	-$129.12M	–
FY2014	Dec 31, 2014	-$59.55M	–
FY2013	Dec 31, 2013	-$50.82M	–
FY2012	Dec 31, 2012	-$67.17M	–
FY2011	Dec 31, 2011	-$78.09M	–

Quarterly ebitda

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$39.76M	–
Q2 FY2026	Jun 30, 2026	$23.74M	–
Q1 FY2026	Mar 31, 2026	-$4.90M	–
Q4 FY2025	Dec 31, 2025	-$20.53M	–
Q3 FY2025	Sep 30, 2025	-$33.68M	–
Q2 FY2025	Jun 30, 2025	-$31.13M	–
Q1 FY2025	Mar 31, 2025	-$21.97M	–
Q4 FY2020	Dec 31, 2020	-$31.35M	–
Q3 FY2020	Sep 30, 2020	-$18.90M	–
Q2 FY2020	Jun 30, 2020	-$7.05M	–
Q1 FY2020	Mar 31, 2020	-$11.79M	–
Q4 FY2019	Dec 31, 2019	-$62.54M	–
Q3 FY2019	Sep 30, 2019	-$28.68M	–
Q2 FY2019	Jun 30, 2019	-$15.40M	–
Q1 FY2019	Mar 31, 2019	-$35.28M	–
Q4 FY2018	Dec 31, 2018	-$260.19M	–
Q3 FY2018	Sep 30, 2018	-$50.03M	–
Q2 FY2018	Jun 30, 2018	-$26.31M	–
Q1 FY2018	Mar 31, 2018	-$33.86M	–
Q4 FY2017	Dec 31, 2017	-$18.23M	–
Q3 FY2017	Sep 30, 2017	-$36.76M	–
Q2 FY2017	Jun 30, 2017	-$27.78M	–
Q1 FY2017	Mar 31, 2017	-$23.98M	–
Q4 FY2016	Dec 31, 2016	-$25.68M	–